Publications
Publications
Show Results For
- All HBS Web
(163)
- Faculty Publications (34)
Novartis
→
Page 1 of 34
Results →
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- 24 Feb 2022
- Other Presentation
The Fearless ICU
By: Amy C. Edmondson
The last 24 months have pushed ICU teams around the world to their limits. As we move forward, we need to heal and rebuild our critical care teams. Healthcare more than ever will require ICU teams to perform at the highest levels and to continuously innovate to deliver... View Details
- 4 Oct 2021
- Other Presentation
Amy Edmondson, Professor Leadership & Management at Harvard
By: Amy C. Edmondson and Guy Bloom
Amy C. Edmondson is an American scholar of leadership, teaming, and organizational learning. She is currently the Novartis Professor of Leadership at Harvard Business School.
Amy is the author of seven books and more than 75 articles and case studies.
She is... View Details
She is... View Details
- 2 Sep 2021
- Interview
Amy Edmondson
By: Amy C. Edmondson and Deepak Jayaraman
Amy C. Edmondson is the Novartis Professor of Leadership and Management at the Harvard Business School.
Amy has been recognized by the biannual Thinkers50 global ranking of management thinkers since 2011, and most recently was ranked #3 in 2019. She studies teaming,... View Details
- 15 Jul 2021
- Interview
The Secret to Building a Higher-Performing Company—Amy Edmondson
By: Amy C. Edmondson and Jason Marc Campbell
Research shows that organizations with higher levels of psychological safety perform better on almost any metric or KPI than organizations with a low psychological safety score. Psychological safety is "a belief that one will not be punished or humiliated for speaking... View Details
- 12 Jul 2021
- Interview
LeadershipLIVE™—Dr. Amy Edmondson
By: Amy C. Edmondson and Tom Matthews
Dr. Amy Edmondson has made a career studying leadership in influential businesses, becoming a world-class leader in the process. A protege of the late Larry Wilson, she’s built a rock-solid foundation on his wisdom. Dr. Edmondson is now the Novartis Professor of... View Details
- 28 Dec 2020
- Interview
Psychological Safety and Fearless Organisations
By: Amy C. Edmondson and Vesna Lucca
In This Podcast:
• The ugly and beauty in transformational change
• Why don’t all companies create psychological safety
• Her passion to create a better workplace
• Buckminster Fuller
• The importance of system thinking
• The power... View Details
• The ugly and beauty in transformational change
• Why don’t all companies create psychological safety
• Her passion to create a better workplace
• Buckminster Fuller
• The importance of system thinking
• The power... View Details
- November 2019
- Case
The Genesis Lab at Novartis
By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details
- 14 Apr 2019
- Interview
How to Build Psychological Safety, with Amy Edmondson
By: Amy C. Edmondson and Dave Stachowiak
Amy Edmondson is the Novartis Professor of Leadership and Management at the Harvard Business School. She has been recognized by the Thinkers50 global ranking of management thinkers for many years and was honored with their Talent Award in 2017. Amy is the author of... View Details
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
- April 2015
- Supplement
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
- December 2014 (Revised October 2017)
- Case
Social Business at Novartis: Arogya Parivar
By: Michael E. Porter, Mark R. Kramer and David Lane
Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details
- March 2014
- Case
Novartis' Sandoz: Between Generics and Pharma
By: Krishna Palepu and Carin-Isabel Knoop
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details
- May 2013 (Revised October 2014)
- Case
Novartis: Leading a Global Enterprise
By: William W. George, Krishna G. Palepu and Carin-Isabel Knoop
Novartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise... View Details
Keywords: Multinational Firms and Management; Talent and Talent Management; Organizational Structure; Organizational Culture; Success; Globalized Markets and Industries; Management Teams; Change Management; Business History; Mergers and Acquisitions; Global Strategy; Health Care and Treatment; Pharmaceutical Industry; Health Industry; Switzerland
- June 2012
- Teaching Note
Cynthia Hogan and the Birth of Novartis (TN)
By: Rosabeth M. Kanter and Matthew Bird
- 2011
- Interview
Creating Shared Value: Connecting Business, Societal Value and Opportunity
By: Michael E. Porter, Mark R. Kramer and Jane Nelson
Michael Porter, Mark Kramer and Jane Nelson discuss creating shared value and give examples from HP, Nestlé and Novartis on how corporations can put this approach into practice. For more more information on creating shared value, visit www.fsg.org View Details
- April 2009 (Revised April 2009)
- Case
Immusol and Novartis
By: Regina E. Herzlinger, Keyne M. Monson, Juan D. Betancourt and Victor Li
Should Immusol strive to become a fully integrated pharmaceutical company? How should a small pharmaceutical company structure a deal for its novel technology with the giant Novartis? View Details